Oh, D., Kim, J. W., Park, J. O., Choi, H. J., Yoon, J., Kang, M., Hong, J. Y., Lee, C., Kwon, H., Kim, E., Cha, H., Kim, J., Kim, J. (2025). An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4227